Cue Biopharma (CUE) Stock Forecast, Price Target & Predictions
CUE Stock Forecast
Cue Biopharma stock forecast is as follows: an average price target of $5.00 (represents a 748.90% upside from CUE’s last price of $0.59) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
CUE Price Target
The average price target for Cue Biopharma (CUE) is $5.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $2.00. This represents a potential 748.90% upside from CUE's last price of $0.59.
CUE Analyst Ratings
According to 2 Wall Street analysts, Cue Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for CUE stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cue Biopharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 26, 2024 | Reni Benjamin | JMP Securities | $2.00 | $0.70 | 184.37% | 239.56% |
| Mar 13, 2024 | Maury Raycroft | Jefferies | $6.00 | $2.15 | 179.07% | 918.68% |
| Nov 20, 2022 | Edward Tenthoff | Piper Sandler | $7.00 | $3.22 | 117.39% | 1088.46% |
The latest Cue Biopharma stock forecast, released on Jul 26, 2024 by Reni Benjamin from JMP Securities, set a price target of $2.00, which represents a 184.37% increase from the stock price at the time of the forecast ($0.70), and a 239.56% increase from CUE last price ($0.59).
Cue Biopharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $2.00 | $4.00 |
| Last Closing Price | $0.59 | $0.59 | $0.59 |
| Upside/Downside | -100.00% | 239.56% | 579.12% |
In the current month, the average price target of Cue Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cue Biopharma's last price of $0.59. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 26, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 26, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Apr 09, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| Apr 09, 2024 | Piper Sandler | Buy | Buy | Hold |
| Nov 20, 2022 | Piper Sandler | - | Overweight | Initialise |
Cue Biopharma's last stock rating was published by Piper Sandler on Jul 26, 2024. The company gave CUE a "Overweight" rating, the same as its previous rate.
Cue Biopharma Financial Forecast
Cue Biopharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $1.38M | $187.00K | $151.23K | $68.00K | - | $1.00M | $1.57M | $2.40M | $2.74M | $1.55M | $475.32K | $704.00K | $1.07M | $900.00K | $1.05M | $984.00K | $1.05M | $370.00K | $449.00K |
| Avg Forecast | $1.53M | $1.48M | $1.43M | $1.10M | $1.91M | $1.52M | $1.29M | $1.21M | $966.67K | $1.31M | $907.50K | $1.95M | $103.75K | $513.50K | $1.13M | $3.05M | $1.14M | $2.40M | $1.06M | $585.60K | $1.49M | $1.27M | $930.00K | $1.36M | $836.00K | $225.00K | $225.00K | $225.00K | $275.19K |
| High Forecast | $2.80M | $2.71M | $2.63M | $2.02M | $3.51M | $2.95M | $2.37M | $2.22M | $2.08M | $2.40M | $1.67M | $3.58M | $190.44K | $942.54K | $1.13M | $4.86M | $1.81M | $3.81M | $1.68M | $932.30K | $2.37M | $2.02M | $1.48M | $2.16M | $1.33M | $358.21K | $358.21K | $358.21K | $330.23K |
| Low Forecast | $200.75K | $194.30K | $188.20K | $144.87K | $251.45K | $283.60K | $169.60K | $159.29K | $68.56K | $172.04K | $119.41K | $256.58K | $13.65K | $67.56K | $1.13M | $607.76K | $226.67K | $476.62K | $210.35K | $116.54K | $296.42K | $252.84K | $185.07K | $270.25K | $166.37K | $44.78K | $44.78K | $44.78K | $220.15K |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 7 | 8 | 7 | 11 | 10 | 6 | 11 | 6 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.52% | 0.10% | 1.46% | 0.13% | - | 0.33% | 1.38% | 1.00% | 2.59% | 2.65% | 0.32% | 0.55% | 1.16% | 0.66% | 1.26% | 4.37% | 4.69% | 1.64% | 1.63% |
Cue Biopharma's average Quarter revenue forecast for Sep 23 based on 2 analysts is $1.31M, with a low forecast of $172.04K, and a high forecast of $2.40M. CUE's average Quarter revenue forecast represents a -5.39% decrease compared to the company's last Quarter revenue of $1.38M (Jun 23).
Cue Biopharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 7 | 8 | 7 | 11 | 10 | 6 | 11 | 6 | 14 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-12.10M | $-11.86M | $-13.67M | $-10.29M | - | $-13.93M | $-7.58M | $-12.68M | $-9.96M | $-12.19M | $-10.64M | $-9.76M | $-11.56M | $-11.56M | $-7.39M | $-5.77M | $-7.89M | $-10.06M | $-12.37M |
| Avg Forecast | $-1.53M | $-1.48M | $-1.43M | $-1.10M | $-1.91M | $-1.52M | $-1.29M | $-1.21M | $-966.67K | $-1.31M | $-907.50K | $-1.95M | $-103.75K | $-11.25M | $-1.13M | $-13.60M | $-1.14M | $-12.03M | $-12.10M | $-11.22M | $-1.49M | $-1.27M | $-12.90M | $-7.26M | $-836.00K | $-7.48M | $-9.30M | $-6.54M | $-5.01M |
| High Forecast | $-200.75K | $-194.30K | $-188.20K | $-144.87K | $-251.45K | $-283.60K | $-169.60K | $-159.29K | $-68.56K | $-172.04K | $-119.41K | $-256.58K | $-13.65K | $-9.00M | $-1.13M | $-10.88M | $-226.67K | $-9.62M | $-9.68M | $-8.98M | $-296.42K | $-252.84K | $-10.32M | $-5.81M | $-166.37K | $-5.98M | $-7.44M | $-5.23M | $-4.01M |
| Low Forecast | $-2.80M | $-2.71M | $-2.63M | $-2.02M | $-3.51M | $-2.95M | $-2.37M | $-2.22M | $-2.08M | $-2.40M | $-1.67M | $-3.58M | $-190.44K | $-13.49M | $-1.13M | $-16.32M | $-1.81M | $-14.43M | $-14.52M | $-13.47M | $-2.37M | $-2.02M | $-15.48M | $-8.72M | $-1.33M | $-8.97M | $-11.16M | $-7.85M | $-6.01M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 13.34% | 6.08% | 131.78% | 0.92% | - | 1.02% | 6.65% | 1.05% | 0.82% | 1.09% | 7.15% | 7.68% | 0.90% | 1.59% | 8.84% | 0.77% | 0.85% | 1.54% | 2.47% |
undefined analysts predict CUE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cue Biopharma's previous annual EBITDA (undefined) of $NaN.
Cue Biopharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 7 | 8 | 7 | 11 | 10 | 6 | 11 | 6 | 14 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-13.19M | $-13.21M | $-14.45M | $-10.88M | - | $-14.27M | $-8.39M | $-12.99M | $-10.28M | $-12.51M | $-11.10M | $-10.03M | $-10.83M | $-12.82M | $-8.92M | $-6.99M | $-9.52M | $-11.27M | $-12.56M |
| Avg Forecast | $-7.86M | $-7.86M | $-7.69M | $-8.53M | $-6.27M | $-9.16M | $-14.05M | $-14.15M | $-15.05M | $-16.31M | $-15.30M | $-13.92M | $-14.80M | $-11.53M | $-19.29M | $-13.92M | $-19.89M | $-12.33M | $-12.48M | $-11.52M | $-16.49M | $-17.16M | $-12.09M | $-8.06M | $-21.10M | $-9.06M | $-11.22M | $-7.32M | $-5.09M |
| High Forecast | $1.01M | $1.01M | $992.03K | $1.10M | $808.74K | $-7.49M | $1.81M | $1.82M | $-13.50M | $2.10M | $1.97M | $1.80M | $1.91M | $-9.22M | $-19.29M | $-11.14M | $821.53K | $-9.86M | $-9.99M | $-9.21M | $681.13K | $708.62K | $-9.67M | $-6.45M | $871.18K | $-7.24M | $-8.98M | $-5.86M | $-4.07M |
| Low Forecast | $-16.40M | $-16.40M | $-16.05M | $-17.79M | $-13.08M | $-11.24M | $-29.31M | $-29.52M | $-17.65M | $-34.02M | $-31.93M | $-29.05M | $-30.88M | $-13.83M | $-19.29M | $-16.71M | $-35.21M | $-14.79M | $-14.98M | $-13.82M | $-29.19M | $-30.37M | $-14.51M | $-9.67M | $-37.33M | $-10.87M | $-13.47M | $-8.79M | $-6.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.86% | 0.95% | 0.98% | 0.94% | - | 1.03% | 0.42% | 1.05% | 0.82% | 1.09% | 0.67% | 0.58% | 0.90% | 1.59% | 0.42% | 0.77% | 0.85% | 1.54% | 2.47% |
Cue Biopharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CUE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Cue Biopharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 7 | 8 | 7 | 11 | 10 | 6 | 11 | 6 | 14 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $4.25M | $4.18M | $3.70M | $3.53M | - | $5.16M | $4.67M | $4.10M | $4.28M | $4.25M | $3.45M | $3.32M | $3.90M | $3.99M | $3.10M | $2.78M | $3.42M | $3.44M | $2.90M |
| Avg Forecast | $7.62M | $7.38M | $7.15M | $5.50M | $9.55M | $7.58M | $6.44M | $6.05M | $4.83M | $6.53M | $4.53M | $9.74M | $518.33K | $2.57M | $5.65M | $15.26M | $5.69M | $11.97M | $5.28M | $2.93M | $7.44M | $6.35M | $4.65M | $6.78M | $4.18M | $1.12M | $1.12M | $1.12M | $1.37M |
| High Forecast | $13.99M | $13.54M | $13.12M | $10.10M | $17.52M | $14.74M | $11.82M | $11.10M | $10.38M | $11.99M | $8.32M | $17.88M | $951.41K | $4.71M | $5.65M | $24.29M | $9.06M | $19.05M | $8.41M | $4.66M | $11.85M | $10.11M | $7.40M | $10.80M | $6.65M | $1.79M | $1.79M | $1.79M | $1.65M |
| Low Forecast | $1.00M | $970.71K | $940.25K | $723.76K | $1.26M | $1.42M | $847.35K | $795.81K | $342.51K | $859.50K | $596.56K | $1.28M | $68.20K | $337.55K | $5.65M | $3.04M | $1.13M | $2.38M | $1.05M | $582.22K | $1.48M | $1.26M | $924.63K | $1.35M | $831.17K | $223.70K | $223.70K | $223.70K | $1.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.94% | 0.43% | 7.15% | 1.38% | - | 0.34% | 0.82% | 0.34% | 0.81% | 1.45% | 0.46% | 0.52% | 0.84% | 0.59% | 0.74% | 2.47% | 3.04% | 3.06% | 2.11% |
Cue Biopharma's average Quarter SG&A projection for Sep 23 is $6.53M, based on 2 Wall Street analysts, with a range of $859.50K to $11.99M. The forecast indicates a 53.74% rise compared to CUE last annual SG&A of $4.25M (Jun 23).
Cue Biopharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 3 | 7 | 8 | 7 | 11 | 10 | 6 | 11 | 6 | 14 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.29 | $-0.30 | $-0.41 | $-0.31 | - | $-0.44 | $-0.27 | $-0.41 | $-0.33 | $-0.41 | $-0.37 | $-0.34 | $-0.38 | $-0.48 | $-0.37 | $-0.31 | $-0.46 | $-0.54 | $-0.62 |
| Avg Forecast | $-0.16 | $-0.16 | $-0.15 | $-0.17 | $-0.13 | $-0.18 | $-0.28 | $-0.28 | $-0.30 | $-0.33 | $-0.30 | $-0.28 | $-0.29 | $-0.38 | $-0.39 | $-0.40 | $-0.42 | $-0.39 | $-0.42 | $-0.38 | $-0.35 | $-0.36 | $-0.41 | $-0.33 | $-0.45 | $-0.44 | $-0.46 | $-0.40 | $-0.15 |
| High Forecast | $0.02 | $0.02 | $0.02 | $0.02 | $0.02 | $-0.15 | $0.04 | $0.04 | $-0.27 | $0.04 | $0.04 | $0.04 | $0.04 | $0.05 | $-0.39 | $0.02 | $0.02 | $0.02 | $0.02 | $0.02 | $0.01 | $0.02 | $0.02 | $0.01 | $0.02 | $0.02 | $0.02 | $0.02 | $-0.12 |
| Low Forecast | $-0.33 | $-0.33 | $-0.32 | $-0.35 | $-0.26 | $-0.22 | $-0.58 | $-0.59 | $-0.35 | $-0.68 | $-0.64 | $-0.58 | $-0.62 | $-0.79 | $-0.39 | $-0.71 | $-0.75 | $-0.68 | $-0.74 | $-0.67 | $-0.62 | $-0.64 | $-0.72 | $-0.59 | $-0.79 | $-0.78 | $-0.81 | $-0.71 | $-0.18 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.95% | 1.08% | 1.39% | 0.82% | - | 1.09% | 0.64% | 1.06% | 0.79% | 1.08% | 1.07% | 0.93% | 0.94% | 1.44% | 0.83% | 0.70% | 1.00% | 1.35% | 4.13% |
According to undefined Wall Street analysts, Cue Biopharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CUE previous annual EPS of $NaN (undefined).
Cue Biopharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | $0.32 | $14.00 | 4275.00% | Buy |
| CUE | Cue Biopharma | $0.59 | $5.00 | 747.46% | Buy |
| PYPD | PolyPid | $3.47 | $25.00 | 620.46% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| INMB | INmune Bio | $5.46 | $22.00 | 302.93% | Buy |
| DRMA | Dermata Therapeutics | $1.58 | $6.00 | 279.75% | Buy |
| FENC | Fennec Pharmaceuticals | $5.47 | $15.75 | 187.93% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ANIX | Anixa Biosciences | $3.35 | $8.00 | 138.81% | Buy |
| TCRX | TScan Therapeutics | $5.74 | $12.00 | 109.06% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
CUE Forecast FAQ
Is Cue Biopharma a good buy?
Yes, according to 2 Wall Street analysts, Cue Biopharma (CUE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of CUE's total ratings.
What is CUE's price target?
Cue Biopharma (CUE) average price target is $5 with a range of $2 to $7, implying a 748.90% from its last price of $0.589. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cue Biopharma stock go up soon?
According to Wall Street analysts' prediction for CUE stock, the company can go up by 748.90% (from the last price of $0.589 to the average price target of $5), up by 1088.46% based on the highest stock price target, and up by 239.56% based on the lowest stock price target.
Can Cue Biopharma stock reach $1?
CUE's average twelve months analyst stock price target of $5 supports the claim that Cue Biopharma can reach $1 in the near future.
What are Cue Biopharma's analysts' financial forecasts?
Cue Biopharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $5.93M (high $11.05M, low $863.94K), average EBITDA is $-5.928M (high $-864K, low $-11.045M), average net income is $-43.627M (high $-3.047M, low $-83.149M), average SG&A $29.62M (high $55.18M, low $4.32M), and average EPS is $-0.869 (high $-0.0607, low $-1.657). CUE's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5.53M (high $10.16M, low $728.11K), average EBITDA is $-5.534M (high $-728K, low $-10.157M), average net income is $-31.945M (high $4.12M, low $-66.642M), average SG&A $27.65M (high $50.75M, low $3.64M), and average EPS is $-0.637 (high $0.0821, low $-1.328).
Did the CUE's actual financial results beat the analysts' financial forecasts?
Based on Cue Biopharma's last annual report (Dec 2022), the company's revenue was $1.25M, which missed the average analysts forecast of $4.8M by -74.07%. Apple's EBITDA was $-50.767M, beating the average prediction of $-26.083M by 94.63%. The company's net income was $-52.796M, missing the average estimation of $-59.543M by -11.33%. Apple's SG&A was $16.17M, missing the average forecast of $23.99M by -32.61%. Lastly, the company's EPS was $-1.48, beating the average prediction of $-1.464 by 1.08%. In terms of the last quarterly report (Jun 2023), Cue Biopharma's revenue was $1.38M, beating the average analysts' forecast of $907.5K by 52.29%. The company's EBITDA was $-12.104M, beating the average prediction of $-908K by 1233.77%. Cue Biopharma's net income was $-13.185M, missing the average estimation of $-15.303M by -13.84%. The company's SG&A was $4.25M, missing the average forecast of $4.53M by -6.28%. Lastly, the company's EPS was $-0.29, missing the average prediction of $-0.305 by -4.92%